Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited

SIMPLE SUMMARY: Multimodal treatment of rectal cancer is undergoing dynamic change. In phase II/III multimodal rectal cancer trials, long-term survival remains the most objective endpoint for reporting treatment efficacy, but long follow-up is required, and there is a risk that the study results wil...

Descripción completa

Detalles Bibliográficos
Autores principales: Diefenhardt, Markus, Schlenska-Lange, Anke, Kuhnt, Thomas, Kirste, Simon, Piso, Pompiliu, Bechstein, Wolf O., Hildebrandt, Guido, Ghadimi, Michael, Hofheinz, Ralf-Dieter, Rödel, Claus, Fokas, Emmanouil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367426/
https://www.ncbi.nlm.nih.gov/pubmed/35954320
http://dx.doi.org/10.3390/cancers14153658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367426/
https://www.ncbi.nlm.nih.gov/pubmed/35954320
http://dx.doi.org/10.3390/cancers14153658

Ejemplares similares